Menu
Three patient groups recently told a federal appeals court that a 340B rebate model “is essential to the effort to bring transparency to 340B.” One of those groups did not disclose its financial ties to drugmakers, and another is out of compliance with state public reporting laws.

Patient Groups Back Drugmakers in 340B Rebate Appeal, Without Disclosing Drug Industry Funding or Missed Compliance Deadline

William Newton, Associate Editor/Senior Writer 340B Report Views
Three patient groups are urging a federal appeals court to back drugmaker 340B rebate models they argue would bring transparency [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Alkermes, Novartis Exempt Additional States from 340B Contract Pharmacy Restrictions

Safeguard Your 340B Program and Increase Compliance Through Automated, 100% Audit Workflows

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Quick verification required before signup

Site Footer Live